About This Video
Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Results from Phase 3b Studies with Durezol Dosed Prior to Surgery
Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that Durezol? (difluprednate ophthalmic emulsion) 0.05% is now commercially available. Durezol, which was approved by the U.S. Food and Drug Administration in June 2008, is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery.
To view Multimedia News Release, go to http://www.prnewswire.com/mnr/durezol/34934/
This website uses Adobe® Flash™ Player 9
Download Flash Now
If you are using Internet Explorer, you will need to restart your browser
after installing Flash.
Adobe and Flash are registered trademarks of Adobe Systems incorporated.
All rights reserved.
